Treatment Information

Back

Liver Cancer treatment details. Chemotherapy, Biologic therapy.

UCL Medical School, London, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:5City/State/Province:London
Treatments:Chemotherapy, Biologic therapyHospital:UCL Medical School
Drugs:Journal:Link
Date:Feb 2013

Description:

Patients:
This phase 2 study involved untreated hepatocellular carcinoma patients who were divided into two separate treatment groups. Group A consisted of 42 patients with a median age of 62.6 years and 83.3% male. Group B had 44 patients with a median age of 63.2 years and 88.6% male.

Treatment:
Patients in group A were treated with a type of biologic therapy called transarterial embolization (TAE) in which blood supply to the tumor is blocked, causing tumor cells to die.

Patients in group B were treated with TACE, a combination of chemotherapy with cisplatin and the biologic therapy called transarterial embolization (TAE) in which blood supply to the tumor is blocked, causing tumor cells to die.

Toxicities:
There was one treatment-related death due to kidney and liver failure in group A. Grade 4 pain and fatigue were also reported.

There was one treatment-related death due to liver failure in group B. Grade 4 pain and grade 3 vomiting were also reported.

Results:
The median overall survival for groups A and B was 17.3 and 16.3 months, respectively.

Correspondence: Dr. T Meyer; email: [email protected]



Back